Literature DB >> 19912255

Anti-transglutaminase antibodies in non-coeliac children suffering from infectious diseases.

F Ferrara1, S Quaglia, I Caputo, C Esposito, M Lepretti, S Pastore, R Giorgi, S Martelossi, G Dal Molin, N Di Toro, A Ventura, T Not.   

Abstract

Anti-transglutaminase antibodies are the diagnostic markers of coeliac disease. A role is suggested for infectious agents in the production of anti-transglutaminase antibodies. The aim was to measure positive anti-transglutaminase antibody levels in children with infectious diseases and to compare immunological and biological characteristics of the anti-transglutaminase antibodies derived from these children with that from coeliac patients. Two hundred and twenty-two children suffering from infectious diseases were enrolled prospectively along with seven biopsy-proven coeliacs. Serum samples were tested for anti-transglutaminase antibodies and anti-endomysium antibodies; positive samples were tested for coeliac-related human leucocyte antigen (HLA)-DQ2/8 and anti-viral antibodies. Purified anti-transglutaminase antibodies from the two study groups were tested for urea-dependent avidity, and their ability to induce cytoskeletal rearrangement and to modulate cell-cycle in Caco-2 cells, using phalloidin staining and bromodeoxyuridine incorporation assays, respectively. Nine of 222 children (4%) tested positive to anti-transglutaminase, one of whom also tested positive for anti-endomysium antibodies. This patient was positive for HLA-DQ2 and was diagnosed as coeliac following intestinal biopsy. Of the eight remaining children, two were positive for HLA-DQ8. Levels of anti-transglutaminase returned to normal in all subjects, despite a gluten-containing diet. Purified anti-transglutaminase of the two study groups induced actin rearrangements and cell-cycle progression. During an infectious disease, anti-transglutaminase antibodies can be produced temporarily and independently of gluten. The infection-triggered anti-transglutaminase antibodies have the same biological properties as that of the coeliacs, with the same in-vivo potential for damage.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19912255      PMCID: PMC2810390          DOI: 10.1111/j.1365-2249.2009.04054.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  19 in total

1.  Anti-transglutaminase antibodies and age.

Authors:  Valentina Baldas; Tarcisio Not; Alberto Tommasini; Filippo Ansaldi; Sergio Demarini; Daniele Sblattero; Roberto Marzari; Lucio Torelli; Alberto Burlina; Claudio Tiribelli; Alessandro Ventura
Journal:  Clin Chem       Date:  2004-10       Impact factor: 8.327

Review 2.  What are the sensitivity and specificity of serologic tests for celiac disease? Do sensitivity and specificity vary in different populations?

Authors:  Ivor D Hill
Journal:  Gastroenterology       Date:  2005-04       Impact factor: 22.682

3.  Autoantibodies in coeliac disease: tissue transglutaminase--guilt by association?

Authors:  L M Sollid; O Molberg; S McAdam; K E Lundin
Journal:  Gut       Date:  1997-12       Impact factor: 23.059

4.  Anti-endomysium antibody on human umbilical cord vein tissue: an inexpensive and sensitive diagnostic tool for the screening of coeliac disease.

Authors:  T Not; A Città; A Lucchesi; G Torre; S Martelossi; A Ventura
Journal:  Eur J Pediatr       Date:  1997-08       Impact factor: 3.183

5.  Humoral immune response to tissue transglutaminase is related to epithelial cell proliferation in celiac disease.

Authors:  Maria V Barone; Ivana Caputo; Maria T Ribecco; Maria Maglio; Roberto Marzari; Daniele Sblattero; Riccardo Troncone; Salvatore Auricchio; Carla Esposito
Journal:  Gastroenterology       Date:  2007-01-21       Impact factor: 22.682

6.  Affinity maturation of immunoglobulin A anti-tissue transglutaminase autoantibodies during development of coeliac disease.

Authors:  A Westerlund; M Ankelo; S Simell; J Ilonen; M Knip; O Simell; A E Hinkkanen
Journal:  Clin Exp Immunol       Date:  2007-02-07       Impact factor: 4.330

Review 7.  The role of the immune response against tissue transglutaminase in the pathogenesis of coeliac disease.

Authors:  Tobias Freitag; Hendrik Schulze-Koops; Gerald Niedobitek; Gerry Melino; Detlef Schuppan
Journal:  Autoimmun Rev       Date:  2004-02       Impact factor: 9.754

8.  In celiac disease, a subset of autoantibodies against transglutaminase binds toll-like receptor 4 and induces activation of monocytes.

Authors:  Giovanna Zanoni; Riccardo Navone; Claudio Lunardi; Giuseppe Tridente; Caterina Bason; Simona Sivori; Ruggero Beri; Marzia Dolcino; Enrico Valletta; Roberto Corrocher; Antonio Puccetti
Journal:  PLoS Med       Date:  2006-09       Impact factor: 11.069

9.  Mass screening for coeliac disease using antihuman transglutaminase antibody assay.

Authors:  A Tommasini; T Not; V Kiren; V Baldas; D Santon; C Trevisiol; I Berti; E Neri; T Gerarduzzi; I Bruno; A Lenhardt; E Zamuner; A Spanò; S Crovella; S Martellossi; G Torre; D Sblattero; R Marzari; A Bradbury; G Tamburlini; A Ventura
Journal:  Arch Dis Child       Date:  2004-06       Impact factor: 3.791

10.  The analysis of the fine specificity of celiac disease antibodies using tissue transglutaminase fragments.

Authors:  Daniele Sblattero; Fiorella Florian; Elisabetta Azzoni; Trevin Zyla; Min Park; Valentina Baldas; Tarcisio Not; Alessandro Ventura; Andrew Bradbury; Roberto Marzari
Journal:  Eur J Biochem       Date:  2002-11
View more
  11 in total

Review 1.  Screening for celiac disease in the general population and in high-risk groups.

Authors:  Jonas F Ludvigsson; Timothy R Card; Katri Kaukinen; Julio Bai; Fabiana Zingone; David S Sanders; Joseph A Murray
Journal:  United European Gastroenterol J       Date:  2015-04       Impact factor: 4.623

Review 2.  Anti-type 2 transglutaminase antibodies as modulators of type 2 transglutaminase functions: a possible pathological role in celiac disease.

Authors:  Stefania Martucciello; Gaetana Paolella; Carla Esposito; Marilena Lepretti; Ivana Caputo
Journal:  Cell Mol Life Sci       Date:  2018-08-22       Impact factor: 9.261

3.  Evaluation of the ESPGHAN Celiac Guidelines in a North American Pediatric Population.

Authors:  Dominica Gidrewicz; Kathryn Potter; Cynthia L Trevenen; Martha Lyon; J Decker Butzner
Journal:  Am J Gastroenterol       Date:  2015-03-31       Impact factor: 10.864

Review 4.  Celiac disease in children and adolescents: special considerations.

Authors:  Kimberly P Newton; Shereen A Singer
Journal:  Semin Immunopathol       Date:  2012-05-02       Impact factor: 9.623

5.  Celiac disease diagnosis and management: a 46-year-old woman with anemia.

Authors:  Daniel Leffler
Journal:  JAMA       Date:  2011-10-12       Impact factor: 56.272

6.  Children with celiac disease are more likely to have attended hospital for prior respiratory syncytial virus infection.

Authors:  Anna Röckert Tjernberg; Jonas F Ludvigsson
Journal:  Dig Dis Sci       Date:  2014-02-09       Impact factor: 3.199

7.  Lack of evidence of rotavirus-dependent molecular mimicry as a trigger of coeliac disease.

Authors:  F Ziberna; G De Lorenzo; V Schiavon; F Arnoldi; S Quaglia; L De Leo; S Vatta; S Martelossi; O R Burrone; A Ventura; T Not
Journal:  Clin Exp Immunol       Date:  2016-09-29       Impact factor: 4.330

8.  Celiac disease in adult patients: specific autoantibodies in the diagnosis, monitoring, and screening.

Authors:  Evagelia Trigoni; Alexandra Tsirogianni; Elena Pipi; Gerassimos Mantzaris; Chryssa Papasteriades
Journal:  Autoimmune Dis       Date:  2014-04-03

9.  Efficacy Study of Anti-Endomysium Antibodies for Celiac Disease Diagnosis: A Retrospective Study in a Spanish Pediatric Population.

Authors:  María Roca; Ester Donat; Natalia Marco-Maestud; Etna Masip; David Hervás-Marín; David Ramos; Begoña Polo; Carmen Ribes-Koninckx
Journal:  J Clin Med       Date:  2019-12-11       Impact factor: 4.241

Review 10.  Molecular Biomarkers for Celiac Disease: Past, Present and Future.

Authors:  Aarón D Ramírez-Sánchez; Ineke L Tan; B C Gonera-de Jong; Marijn C Visschedijk; Iris Jonkers; Sebo Withoff
Journal:  Int J Mol Sci       Date:  2020-11-12       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.